Divi's Laboratories Limited

NSE DIVISLAB.NS

Divi's Laboratories Limited Gross Profit for the year ending March 31, 2024: USD 388.92 M

Divi's Laboratories Limited Gross Profit is USD 388.92 M for the year ending March 31, 2024, a -32.19% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Divi's Laboratories Limited Gross Profit for the year ending March 31, 2023 was USD 573.53 M, a -25.33% change year over year.
Divi's Laboratories Limited Gross Profit for the year ending March 31, 2022 was USD 768.09 M, a 24.04% change year over year.
Divi's Laboratories Limited Gross Profit for the year ending March 31, 2021 was USD 619.24 M, a 46.62% change year over year.
Divi's Laboratories Limited Gross Profit for the year ending March 31, 2020 was USD 422.34 M, a -1.47% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NSE: DIVISLAB.NS

Divi's Laboratories Limited

CEO	Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
IPO Date	March 12, 2003
Location	India
Headquarters	Divi Towers
Employees	9,741
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a range of carotenoids, as well as markets vitamins to nutritional, pharma, food/beverage, and feed industries. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.

Key trends

Past 5 years